Stock ACMELAB THE ACME LABORATORIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials The ACME Laboratories Ltd.

Equities

ACMELAB

BD0491ACME00

Pharmaceuticals

End-of-day quote Dhaka S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
69.1 BDT -1.14% Intraday chart for The ACME Laboratories Ltd. 0.00% -18.71%
Jan. 15 The ACME Laboratories Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
2023 The ACME Laboratories Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 21,139 16,293 13,416 15,595 18,811 18,198
Enterprise Value (EV) 1 30,612 28,359 27,273 29,070 33,506 37,521
P/E ratio 14.8 x 11.3 x 9.26 x 9.94 x 8.91 x 7.9 x
Yield 3.5% 4.55% 3.94% 3.39% 3.37% 3.84%
Capitalization / Revenue 1.43 x 1 x 0.71 x 0.75 x 0.79 x 0.68 x
EV / Revenue 2.07 x 1.74 x 1.44 x 1.4 x 1.4 x 1.39 x
EV / EBITDA 8.32 x 6.76 x 5.6 x 5.97 x 6.16 x 6.38 x
EV / FCF -12.2 x -12.1 x -18.5 x 76 x -29.2 x -7.76 x
FCF Yield -8.19% -8.29% -5.41% 1.32% -3.42% -12.9%
Price to Book 1.2 x 0.89 x 0.7 x 0.78 x 0.87 x 0.78 x
Nbr of stocks (in thousands) 211,602 211,602 211,602 211,602 211,602 211,602
Reference price 2 99.90 77.00 63.40 73.70 88.90 86.00
Announcement Date 11/19/18 11/26/19 11/19/20 12/13/21 11/27/22 11/26/23
1BDT in Million2BDT
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 14,814 16,309 19,004 20,770 23,858 26,948
EBITDA 1 3,679 4,193 4,866 4,870 5,436 5,882
EBIT 1 2,947 3,337 3,681 3,538 4,083 4,474
Operating Margin 19.89% 20.46% 19.37% 17.03% 17.11% 16.6%
Earnings before Tax (EBT) 1 1,955 1,953 1,979 2,073 2,693 2,893
Net income 1 1,427 1,440 1,450 1,569 2,111 2,304
Net margin 9.63% 8.83% 7.63% 7.56% 8.85% 8.55%
EPS 2 6.740 6.807 6.850 7.416 9.976 10.89
Free Cash Flow 1 -2,507 -2,350 -1,476 382.4 -1,147 -4,838
FCF margin -16.92% -14.41% -7.77% 1.84% -4.81% -17.95%
FCF Conversion (EBITDA) - - - 7.85% - -
FCF Conversion (Net income) - - - 24.37% - -
Dividend per Share 2 3.500 3.500 2.500 2.500 3.000 3.300
Announcement Date 11/19/18 11/26/19 11/19/20 12/13/21 11/27/22 11/26/23
1BDT in Million2BDT
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 9,473 12,065 13,858 13,475 14,694 19,324
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.575 x 2.878 x 2.848 x 2.767 x 2.703 x 3.285 x
Free Cash Flow 1 -2,507 -2,350 -1,476 382 -1,147 -4,838
ROE (net income / shareholders' equity) 8.25% 8% 7.76% 8.02% 10.1% 10.2%
ROA (Net income/ Total Assets) 5.89% 6.09% 6.11% 5.54% 6.12% 5.99%
Assets 1 24,232 23,668 23,751 28,349 34,515 38,465
Book Value Per Share 2 83.40 86.70 90.00 95.00 103.0 110.0
Cash Flow per Share 2 5.360 6.510 8.620 7.530 5.850 6.880
Capex 1 3,623 3,520 2,105 1,777 1,751 5,260
Capex / Sales 24.45% 21.58% 11.07% 8.55% 7.34% 19.52%
Announcement Date 11/19/18 11/26/19 11/19/20 12/13/21 11/27/22 11/26/23
1BDT in Million2BDT
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
THE ACME LABORATORIES LTD. Stock The ACME Laboratories Ltd.
-18.71% 133M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 234B
NOVARTIS AG Stock Novartis AG
+4.62% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ACMELAB Stock
  4. Financials The ACME Laboratories Ltd.